Literature DB >> 20655249

Construct validity of the definition of primary graft dysfunction after lung transplantation.

Jason D Christie1, Scarlett Bellamy, Lorraine B Ware, David Lederer, Denis Hadjiliadis, James Lee, Nancy Robinson, A Russell Localio, Keith Wille, Vibha Lama, Scott Palmer, Jonathan Orens, Ann Weinacker, Maria Crespo, Ejigaehu Demissie, Stephen E Kimmel, Steven M Kawut.   

Abstract

BACKGROUND: This study tested the discriminant validity of International Society for Heart and Lung Transplantation (ISHLT) primary graft dysfunction (PGD) grades with lung injury biomarker profiles and survival.
METHODS: The study samples consisted of a multicenter prospective cohort study for the biomarker analysis and a cohort study of 450 patients for the mortality analyses. PGD was defined according to ISHLT consensus at 24, 48, and 72 hours after transplantation. We compared the changes in plasma markers of acute lung injury between PGD grades using longitudinal data models. To test predictive validity, we compared differences in the 30-day mortality and long-term survival according to PGD grade.
RESULTS: PGD Grade 3 demonstrated greater differences between plasma intercellular adhesion molecule 1 (ICAM-1), protein C, and plasminogen activator inhibitor type 1 (PAI-1) levels than did PGD Grades 0 to 2 at 24, 48, and 72 hours after lung transplantation (p < 0.05 for each). Grade 3 had the highest 30-day (test for trend p < 0.001) and overall mortality (log rank p < 0.001), with PGD Grades 1 and 2 demonstrating intermediate risks of mortality. The ability to discriminate both 30-day and overall mortality improved as the time of grading moved away from the time of transplantation (test for trend p < 0.001).
CONCLUSIONS: The ISHLT grading system has good discriminant validity, based on plasma markers of lung injury and mortality. Grade 3 PGD was associated with the most severely altered plasma biomarker profile and the worst outcomes, regardless of the time point of grading. PGD grade at 48 and 72 hours discriminated mortality better than PGD grade at 24 hours.
Copyright © 2010 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20655249      PMCID: PMC2963709          DOI: 10.1016/j.healun.2010.05.013

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  25 in total

1.  Respiratory failure early after lung transplantation: now that we know the extent of the problem, what are the solutions?

Authors:  David Zaas; Scott M Palmer
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

Review 2.  The "injury response": a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes.

Authors:  P F Halloran; J Homik; N Goes; S L Lui; J Urmson; V Ramassar; S M Cockfield
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

3.  Problems of spectrum and bias in evaluating the efficacy of diagnostic tests.

Authors:  D F Ransohoff; A R Feinstein
Journal:  N Engl J Med       Date:  1978-10-26       Impact factor: 91.245

4.  Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation.

Authors:  R C King; O A Binns; F Rodriguez; R C Kanithanon; T M Daniel; W D Spotnitz; C G Tribble; I L Kron
Journal:  Ann Thorac Surg       Date:  2000-06       Impact factor: 4.330

5.  Early elevation of plasma soluble intercellular adhesion molecule-1 in pediatric acute lung injury identifies patients at increased risk of death and prolonged mechanical ventilation.

Authors:  Heidi R Flori; Lorraine B Ware; David Glidden; Michael A Matthay
Journal:  Pediatr Crit Care Med       Date:  2003-07       Impact factor: 3.624

6.  Clinical risk factors for primary graft failure following lung transplantation.

Authors:  Jason D Christie; Robert M Kotloff; Alberto Pochettino; Selim M Arcasoy; Bruce R Rosengard; J Richard Landis; Stephen E Kimmel
Journal:  Chest       Date:  2003-10       Impact factor: 9.410

7.  Risk quantification of early outcome after lung transplantation: donor, recipient, operative, and post-transplant parameters.

Authors:  Yasuo Sekine; Thomas K Waddell; Andrea Matte-Martyn; Andrew F Pierre; Marc de Perrot; Stefan Fischer; John Marshall; John Granton; Michael A Hutcheon; Shaf Keshavjee
Journal:  J Heart Lung Transplant       Date:  2004-01       Impact factor: 10.247

8.  Protein C and thrombomodulin in human acute lung injury.

Authors:  Lorraine B Ware; Xiaohui Fang; Michael A Matthay
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-05-16       Impact factor: 5.464

9.  Respiratory failure after lung transplantation.

Authors:  Wissam M Chatila; Satoshi Furukawa; John P Gaughan; Gerard J Criner
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

Review 10.  Common disorders are quantitative traits.

Authors:  Robert Plomin; Claire M A Haworth; Oliver S P Davis
Journal:  Nat Rev Genet       Date:  2009-10-27       Impact factor: 53.242

View more
  49 in total

1.  CASE 7--2014 Rescue therapy with early extracorporeal membrane oxygenation for primary graft dysfunction after bilateral lung transplantation.

Authors:  Ali M Farooki; Heidi Bazick-Cuschieri; Emily K Gordon; James C Lee; Edward C Cantu; John G Augoustides
Journal:  J Cardiothorac Vasc Anesth       Date:  2013-08-30       Impact factor: 2.628

2.  Objective Estimates Improve Risk Stratification for Primary Graft Dysfunction after Lung Transplantation.

Authors:  R J Shah; J M Diamond; E Cantu; J Flesch; J C Lee; D J Lederer; V N Lama; J Orens; A Weinacker; D S Wilkes; D Roe; S Bhorade; K M Wille; L B Ware; S M Palmer; M Crespo; E Demissie; J Sonnet; A Shah; S M Kawut; S L Bellamy; A R Localio; J D Christie
Journal:  Am J Transplant       Date:  2015-04-15       Impact factor: 8.086

3.  Clinical Risk Factors and Prognostic Model for Primary Graft Dysfunction after Lung Transplantation in Patients with Pulmonary Hypertension.

Authors:  Mary K Porteous; James C Lee; David J Lederer; Scott M Palmer; Edward Cantu; Rupal J Shah; Scarlett L Bellamy; Vibha N Lama; Sangeeta M Bhorade; Maria M Crespo; John F McDyer; Keith M Wille; A Russell Localio; Jonathan B Orens; Pali D Shah; Ann B Weinacker; Selim Arcasoy; David S Wilkes; Lorraine B Ware; Jason D Christie; Steven M Kawut; Joshua M Diamond
Journal:  Ann Am Thorac Soc       Date:  2017-10

4.  Elevated plasma long pentraxin-3 levels and primary graft dysfunction after lung transplantation for idiopathic pulmonary fibrosis.

Authors:  J M Diamond; D J Lederer; S M Kawut; J Lee; V N Ahya; S Bellamy; S M Palmer; V N Lama; S Bhorade; M Crespo; E Demissie; J Sonett; K Wille; J Orens; P D Shah; A Weinacker; D Weill; B A Kohl; C C Deutschman; S Arcasoy; A S Shah; J A Belperio; D Wilkes; J M Reynolds; L B Ware; J D Christie
Journal:  Am J Transplant       Date:  2011-08-22       Impact factor: 8.086

5.  Significant role for microRNA-21 affecting toll-like receptor pathway in primary graft dysfunction after human lung transplantation.

Authors:  Zhongping Xu; Monal Sharma; Andrew Gelman; Ramsey Hachem; Thalachallour Mohanakumar
Journal:  J Heart Lung Transplant       Date:  2016-09-12       Impact factor: 10.247

6.  Postoperative estradiol levels associate with development of primary graft dysfunction in lung transplantation patients.

Authors:  Julie A Bastarache; Joshua M Diamond; Steven M Kawut; David J Lederer; Lorraine B Ware; Jason D Christie
Journal:  Gend Med       Date:  2012-02-22

7.  Radiological patterns of primary graft dysfunction after lung transplantation evaluated by 64-multi-slice computed tomography: a descriptive study.

Authors:  Esther Okeke Belmaati; Ida Steffensen; Claus Jensen; Klaus F Kofoed; Jann Mortensen; Michael B Nielsen; Martin Iversen
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-02-28

8.  Latent class analysis identifies distinct phenotypes of primary graft dysfunction after lung transplantation.

Authors:  Rupal J Shah; Joshua M Diamond; Edward Cantu; James C Lee; David J Lederer; Vibha N Lama; Jonathan Orens; Ann Weinacker; David S Wilkes; Sangeeta Bhorade; Keith M Wille; Lorraine B Ware; Scott M Palmer; Maria Crespo; A Russell Localio; Ejigayehu Demissie; Steven M Kawut; Scarlett L Bellamy; Jason D Christie
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

9.  Genetic variation in the prostaglandin E2 pathway is associated with primary graft dysfunction.

Authors:  Joshua M Diamond; Tatiana Akimova; Altaf Kazi; Rupal J Shah; Edward Cantu; Rui Feng; Matthew H Levine; Steven M Kawut; Nuala J Meyer; James C Lee; Wayne W Hancock; Richard Aplenc; Lorraine B Ware; Scott M Palmer; Sangeeta Bhorade; Vibha N Lama; Ann Weinacker; Jonathan Orens; Keith Wille; Maria Crespo; David J Lederer; Selim Arcasoy; Ejigayehu Demissie; Jason D Christie
Journal:  Am J Respir Crit Care Med       Date:  2014-03-01       Impact factor: 21.405

10.  Gene set enrichment analysis identifies key innate immune pathways in primary graft dysfunction after lung transplantation.

Authors:  E Cantu; D J Lederer; K Meyer; K Milewski; Y Suzuki; R J Shah; J M Diamond; N J Meyer; J W Tobias; D A Baldwin; V M Van Deerlin; K M Olthoff; A Shaked; J D Christie
Journal:  Am J Transplant       Date:  2013-05-24       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.